Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors
Authors:
- Lixin ZhengLZLixin Zheng
- Francis Ka-Ming ChanFCFrancis Ka-Ming Chan
- Michael LenardoMLMichael Lenardo
- 18 September 2005
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 11 (10) , 1066-1072
Abstract
Tumor necrosis factor (TNF)-alpha has an important role in the pathogenesis of autoimmune and inflammatory diseases such as rheumatoid and septic arthritis. The biological effects of TNF-alpha are mediated by binding to TNF receptors TNFR1 (also known as P60) or TNFR2 (also known as P80). The pre-ligand assembly domain (PLAD) is a portion of the extracellular region of TNFRs that mediates receptor-chain association essential for signaling. We found that soluble versions of PLAD, especially those derived from P60, block the biochemical effects of TNF-alpha in vitro and potently inhibit arthritis in animal models. Thus, targeting the PLAD may have clinical value in the treatment of human arthritis and other disorders involving receptors of the TNFR superfamily.Keywords
This publication has 33 references indexed in Scilit:
- RANKL and RANK as novel therapeutic targets for arthritisCurrent Opinion in Rheumatology, 2003
- Osteoclast differentiation and activationNature, 2003
- TNF-R1 Signaling: A Beautiful PathwayScience, 2002
- The TNF and TNF Receptor SuperfamiliesCell, 2001
- The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor functionAnnals of the Rheumatic Diseases, 2000
- Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic MutationsScience, 2000
- EtanerceptDrugs, 1999
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75.Journal of Experimental Medicine, 1995
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994